^
Association details:
Biomarker:EGFR amplification
Cancer:Gastric Cancer
Drug Class:EGFR inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1421P - EGFR inhibition in EGFR-amplified esophagogastric cancer (EGC): Retrospective global experience

Published date:
09/13/2021
Excerpt:
Pts with EGFR-amplified EGC derive clinical benefit from EGFR inhibition, which is most pronounced in the absence of intrinsic resistance mechanisms.